Floatz logo

Eloxatin

Adenocarcinoma of the Colon

Merck Sharp & Dohme LLCPhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
89/ 100

Competitive context

46 Active assets in the Adenocarcinoma of the Colon cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
Irinotecan
SWOG Cancer Research Network
Phase 3BBB
Cetuximab
Merck Sharp & Dohme LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →